Ishita Drugs & Industries Ltd

Ishita Drugs & Industries Ltd., an Ahmedabad-based active pharmaceutical ingredient (API) manufacturer, reported challenging Q4 FY26 results marked by significant revenue contraction and margin compression. The company posted a net profit of ₹0.18 crores for the quarter ended March 2026, representing a 12.50% increase quarter-on-quarter but a concerning 37.93% decline year-on-year. With a modest market capitalisation of ₹24.00 crores, the micro-cap pharma player faces mounting operational headwinds as it navigates a difficult industry environment.

Ishita Drugs & Industries Ltd has witnessed a notable improvement in its valuation parameters, shifting from a fair to an attractive rating. This change comes amid a complex market backdrop where the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios have adjusted favourably relative to historical averages and peer benchmarks, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector.

Ishita Drugs & Industries Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Ishita Drugs & Industries Ltd has witnessed a notable improvement in its valuation parameters, shifting from a fair to an attractive rating despite a recent 4.6% decline in its share price. This micro-cap pharmaceutical player’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more compelling entry point relative to its historical averages and peer group, signalling a potential opportunity for discerning investors amid a challenging sector backdrop.

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 April 2026, reflecting a nuanced improvement in technical indicators and valuation metrics despite persistent challenges in financial trends and quality parameters. The micro-cap pharmaceutical company’s Mojo Score has risen to 31.0, signalling a cautious but positive shift in market sentiment.

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating as of 21 April 2026. This change reflects evolving market perceptions amid a competitive Pharmaceuticals & Biotechnology sector, with the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now aligning more closely with peer averages. Despite a recent 4.38% intraday price rise, the company’s overall mojo grade has been downgraded from Strong Sell to Sell, signalling caution for investors.

Ishita Drugs & Industries Ltd has been downgraded from a Sell to a Strong Sell rating as of 13 Apr 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. Despite some long-term outperformance relative to the Sensex, the company’s micro-cap status, flat recent financial results, and bearish technical signals have prompted a reassessment of its investment appeal.

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 7 April 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite persistent challenges in financial trends and quality parameters. The pharmaceutical micro-cap’s recent price surge of over 10% in a single day underscores renewed investor interest, yet fundamental concerns remain.

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive valuation grade. Despite a recent sharp decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Ishita Drugs & Industries Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade, reflecting evolving market perceptions amid mixed financial metrics and sector dynamics. Despite a robust share price rally in recent weeks, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to peers warrant a cautious approach from investors.

Ishita Drugs & Industries Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹21.00 crores, reported disappointing results for Q2 FY26, with net profit declining 26.32% quarter-on-quarter to ₹0.14 crores from ₹0.30 crores in Q1 FY26. The sharp contraction in profitability came despite the company maintaining a relatively stable operating margin profile, raising concerns about the sustainability of earnings amidst persistent revenue volatility.

Ishita Drugs & Industries Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 January 2026, reflecting a deterioration in technical indicators and persistent fundamental weaknesses. Despite a modest uptick in share price and some valuation appeal, the company’s financial trends and technical signals have raised concerns among analysts, prompting a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Ishita Drugs & Industries Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Dec 2025, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s Mojo Score rose to 34.0, reflecting a modest improvement in market sentiment, while its valuation and financial trends continue to pose challenges for investors.

Ishita Drugs & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 October 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and outlook.

Ishita Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment highlights ongoing challenges in the company’s financial and operational metrics, which investors should consider carefully.